Full TitleA Phase Ib Study of the Safety and Pharmacology of Atezolizumab Administered with Obinutuzumab in Patients with Relapsed/Refractory Follicular Lymphoma or Atezolizumab Administered with Obinutuzumab or Tazemetostat in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (Protocol version 6, 12-AUG-2016)
Follicular lymphoma and diffuse large B-cell lymphoma (DLBCL) often initially respond to treatment, but then come back or continue growing despite standard therapies. Doctors are therefore seeking more effective treatments for these cancers. In this study, researchers want to evaluate the safety and preliminary effectiveness of giving obinutuzumab with atezolizumab in patients with follicular lymphoma or DLBCL that has come back or stopped responding to treatment.
This treatment is a form of immunotherapy. Atezolizumab is designed to improve the immune system’s ability to recognize and destroy cancer cells by blocking PD-L1, a protein made by some cancers. It is approved for treating bladder and lung cancers; its use in this study is considered investigational.
Obinutuzumab triggers an immune response against cancer by binding to a target on lymphoma cells called CD20. Obinutuzumab is already approved for treating chronic lymphocytic leukemia, and it is being assessed for the treatment of other cancers, including lymphoma.
Both drugs are given intravenously (by vein).
To be eligible for this study, patients must meet several criteria, including but not limited to the following:
- Patients must have follicular lymphoma or DLBCL that is positive for CD20.
- Patients’ cancers must have come back or continued to grow within 6 months of completing the prior treatment.
- Patients must be physically well enough that they are fully ambulatory, capable of all self care, and are capable of all but physically strenuous activities. As an example, patients must be well enough that they would be able to carry out office work or light housework.
- This study is for patients age 18 and older.
For more information about this study and to inquire about eligibility, please contact Dr. M. Lia Palomba at 212-639-7186.